Using synthetic control arm studies
in HTA submissions:
An alternative, when RCTs are not feasible

Thursday, June 10th | 11:00am - 12:00pm EDT

Randomized controlled trials (RCTs) are considered the gold standard to determine the efficacy of a new therapy or to evaluate its comparative effectiveness against standard of care. However, regulators acknowledge situations when a RCT may not be operationally or ethically feasible, such as in rare disease patient populations. In those cases, data from single arm trials complemented by synthetic control arms are becoming more commonly accepted as evidence by both regulatory and HTA bodies.

Due to the lack of randomization, submissions based on synthetic control arm studies should apply rigorous analytical methods to adjust for potential confounding caused by imbalances between treatment groups. While regulatory bodies have published guidance on the use of non-randomized evidence, recommendations from HTA agencies have long been limited.

Join us to learn about the challenges and opportunities when using synthetic control arm studies in submissions to HTA agencies. In this webinar, we will:

  • Describe current guidance regarding the use of synthetic control arms from selected HTA agencies in Europe, including Germany and France
  • Analyze and compare critical assessments made by HTA agencies on a number of recent submissions using synthetic control arm trials
  • Illustrate and compare statistical methods to adjust for imbalances in key prognostic variables between treatment groups
  • Summarize recommendations and critical assessments from selected HTA agencies on statistical methods used in synthetic control arm submissions

This program will be beneficial for pharmaceutical, biotech, and medical device professionals working in involved in:

  • Rare diseases
  • Epidemiology
  • Health technology assessment
  • Health economics & outcomes research
  • Marketing
  • Market access, pricing and reimbursement
  • Statistics
  • Real world evidence

Sponsored by:
 



Marketplaces Drive Faster Science:
HEOR, RWE & Market Access Sourcing

June 9, 2021



Informational Webinar:
Online MS Degree, Pharmaceutical Outcomes & Policy

June 23, 2021

 
Click here to view on-demand webinars.
 

In the past you have provided HealthEconomics.Com with your email address. Occasionally you will receive brief announcements on products, services, news and jobs from HealthEconomics.Com or our Partners.

If you don't wish to receive these announcements, you may immediately unsubscribe from this list here, or send your request in writing to HealthEconomics.Com, 1327 Walnut, Jacksonville, FL, 32206. Read more about our privacy policy here. You may also request a copy in writing using the address above.
 

To ensure you continue to receive emails from HealthEconomics.Com, please click here.

Registration does not guarantee acceptance to attend this webinar. All registration will be reviewed by sponsor within 48 hours of receipt. HealthEconomics.Com does not approve or deny any registrations. This responsibility is held solely by the sponsor..